Registry for bladder cancer patients to develop new treatments and biomarkers
Bladder Cancer Longitudinal Biorepository for Development of Novel Therapeutics/Biomarkers
This study is creating a registry to collect information from bladder cancer patients to help develop new treatments and better understand the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Kansas Medical Center Academic / other |
| Locations | 1 site (Kansas City, Kansas) |
| Trial ID | NCT03413982 on ClinicalTrials.gov |
What this trial studies
This study aims to create a comprehensive registry that collects information from patients diagnosed with bladder cancer. By gathering data on long-term outcomes, tumor development, recurrence, and survival, researchers hope to gain insights that could lead to the development of novel therapeutics and biomarkers. The registry will facilitate future research by providing a valuable resource for understanding bladder cancer better. Patients can also participate in other research studies while being part of this registry.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have been diagnosed with or are presumed to have bladder cancer.
Not a fit: Patients who do not have presumed bladder cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatments and better understanding of bladder cancer outcomes for patients.
How similar studies have performed: Other studies utilizing similar registry approaches have shown success in advancing understanding and treatment of various cancers.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who present to clinic with presumed bladder cancer or have a diagnosis of bladder cancer are eligible to participate * Patients can participate in any additional research studies during the patients' participation within this protocol. Exclusion Criteria: * Patients who do not have presumed bladder cancer will not be eligible
Where this trial is running
Kansas City, Kansas
- University of Kansas Medical Center — Kansas City, Kansas, United States (Recruiting)
Study contacts
- Principal investigator: John Taylor, MD — University of Kansas Medical Center
- Study coordinator: Jane Ladesma
- Email: jledesma2@kumc.edu
- Phone: 913-588-8721
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.